Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | HTR5A | P47898 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30511168 | 1.00 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2408663 | 0.89 | MAPT (0.53) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL29622057 | 0.82 | CCNB2 (0.54) | HTR5AHTR1AHTR1DHTR2AHTR2C | |
| SCHEMBL624585 | 0.82 | CCNB2 (0.54) | HTR5AHTR1AHTR1DHTR2AHTR2C | |
| SCHEMBL3593984 | 0.78 | NPC1 (0.52) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10572841 | 0.78 | NPC1 (0.39) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5741470 | 0.77 | ADRA2A (0.51) | HTR5AHTR1AHTR1DHTR2AHTR2C | |
| SCHEMBL31170797 | 0.77 | NOTUM (0.53) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3723532 | 0.77 | SRD5A1 (0.57) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL837526 | 0.77 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026076-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | SEPTERNA, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-112262145-B | 2-aminopyrimidine derivative and preparation method and application thereof | 上海奕拓医药科技有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3212630-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-05-18 | — | — | EP | disclosed |
| US-20210253595-A1 | 2-Aminopyrimidine Derivative and Preparation Method and Use Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210253595-A1 | 2-Aminopyrimidine Derivative and Preparation Method and Use Thereof | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-3786166-A1 | 2-AMINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-3786166-A1 | 2-AMINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2021-03-03 | — | — | EP | disclosed |
| CN-112262145-A | 2-aminopyrimidine derivatives, preparation method and application thereof | 上海奕拓医药科技有限责任公司 | 2021-01-22 | — | — | CN | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
| WO-2010116270-A1 | EP2/4 AGONISTS | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-5656633-A | Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5556857-A | SIGMA RECEPTOR AGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0512525-B1 | Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist | OTSUKA PHARMA CO LTD (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0512525-A1 | Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-11 | — | — | EP | disclosed |
| US-4416884-A | ANTIBIOTIC, BACTERICIDE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | NPC1 3383/4885MAPK13 997/4885MAPK12 1841/4885 |
| US-20210253595-A1 | 2-Aminopyrimidine Derivative and Preparation Method and Use Thereof | IDH1, IDH2, IDH3B | NPC1 3970/4885MAPK13 1558/4885MAPK12 1676/4885 |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | NPC1 2039/4885MAPK13 390/4885MAPK12 1244/4885 |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP17A1, HSD11B1 | NPC1 1135/4885MAPK13 1262/4885MAPK12 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.